Deucravacitinib

• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 Phase III/IV 12 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting
  2023-507039-39-00 Phase III 6 countries Janssen - Cilag International
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting
  2023-505121-14-00 Phase III 6 countries Janssen - Cilag International
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting
  2023-506296-97-00 Phase III 7 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants with Juveni… Recruiting
  2024-517262-41-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 Phase III 15 countries Bristol-Myers Squibb Services Unlimited Company
• GENEPID: A 44-weeks monocentric open study assessing the efficacy and safety of Deucravacitinib in adults with Inflammatory EPidermal GENode… Recruiting
  2022-502879-32-00 Phase II 1 country Centre Hospitalier Universitaire De Nice
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting
  2022-500699-76-00 Phase III 8 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to… Recruiting
  2022-502519-13-00 Phase III 5 countries Bristol-Myers Squibb Services Unlimited Company
• DEUCRALIP Ended
  2022-502991-21-00 Phase II 1 country Rheinische Friedrich Wilhelms Universitaet Bonn
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended
  2022-500700-22-00 Phase III 7 countries Bristol-Myers Squibb Services Unlimited Company
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended
  2023-506257-37-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended
  2023-506256-25-00 Phase III 10 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 2 Clinical Study to Assess the Safety and Efficacy of Deucravacitinib in Participants with Active DLE and/or SCLE Ended
  2023-504161-22-00 Phase II 3 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate-… Ended
  2024-512497-10-00 Phase III 5 countries Takeda Development Center Americas Inc.
• A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety deucravacitinib in patients with chronic hand eczem… Ended
  2023-504298-19-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
• A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment… Ended
  2023-509738-20-00 Phase IV 7 countries AbbVie Deutschland GmbH & Co. KG
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended
  2022-502361-15-00 Phase III 8 countries Bristol-Myers Squibb Services Unlimited Company
• Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus Ended
  2022-502444-13-00 Phase II 4 countries Bristol Myers Squibb International Corporation
• Molecular effects of deucravacitinib on plaque psoriasis and hard-to-treat psoriasis sites. Ended
  2023-508948-22-00 Phase IV 1 country Charite Universitaetsmedizin Berlin KöR
• Immunological and functional characteristics of T memory-like cells in psoriasis under treatment with deucravacitinib. Ended
  2024-510759-37-00 Phase IV 1 country Charite Universitaetsmedizin Berlin KöR

Showing 1–21 of 21 trials